BazaarBaazi

Lookback Archive / Stock Stories

Lookback: How Torrent Pharma’s 5.4% slide in 44 sessions rewrote a bullish script

Lookback: How Torrent Pharma's 5.4% Slide in 44 Sessions Rewrote a Bullish Script

A textbook momentum rally that ran into the 50-DMA and never recovered, all between July 21 and September 4, 2025.

The chart of Torrent Pharmaceuticals between late July and early September 2025 looked, on the surface, like the kind of orderly retracement that defensives are supposed to deliver. A close of ₹3,482 on July 21 had marked the upper edge of a month-long advance off the June lows, and by the time the stock printed an intraday low near ₹3,293 on September 4, the tape had given back roughly 5.4% in 44 sessions. To the half-engaged observer, this was noise. To anyone tracking the daily moving-average stack, the volume signature on the down-days, and the way the September monthly option chain quietly repriced, the move was the cleanest tell the pharma index threw out all quarter. The bullish script that retail had written for Torrent through July, anchored to specialty-pharma operating leverage and a Q1 print that beat at the EBITDA line, was being rewritten in real time, and the writers were not the people on TV.

What follows is a retrospective read of how that script broke, what the weekly structure was actually saying underneath the daily noise, and why the September 4 session in particular deserves to sit in any serious technician's case file.

The weekly structure that nobody wanted to see

Step back to the weekly frame and the picture clarified considerably. Torrent had been one of the cleaner trend stocks in large-cap pharma through 2024 and the first half of 2025, riding the broader narrative that domestic-led pharma names, with low US-generic exposure and a healthy chronic-therapy mix, deserved a premium multiple. The weekly higher-highs sequence that began in late 2023 had carried the stock through three distinct legs, each separated by a sideways consolidation of four to six weeks, each resolving higher.

Torrent Pharma weekly candles, September 2023 to September 2025, with the September 4, 2025 close highlighted Caption: The two-year weekly view showing the rising trend channel from late 2023 and the rejection wick that printed in the week ending September 5, 2025, the first weekly close back inside the prior consolidation band.

By the week of July 21, 2025, the stock had pushed into the upper rail of that channel for the third time inside a calendar year, and on a weekly closing basis it was extended roughly two standard deviations above its 40-week mean. That kind of extension, in a defensive name with no fresh fundamental catalyst pending, has historically been a setup for mean reversion rather than continuation. The market was, in effect, paying a premium for the certainty of Torrent's domestic franchise, and the price had run ahead of the earnings cadence that justified it.

The weekly RSI had also lost its prior peak. Through the 2024 advance, every fresh price high had been confirmed by an RSI print in the high 60s or low 70s. The July 2025 high was made with weekly RSI rolling over from a lower peak, the textbook negative divergence that does not call tops on its own but does soften the bid underneath them. By the week of August 25, the weekly candle had closed below the prior swing low of late June, and the multi-quarter sequence of higher weekly lows was, for the first time in fourteen months, in question.

Daily moving averages: the August 19 break that mattered

The cleanest single-bar signal of the entire window arrived on August 19, 2025. Through the rally from June into late July, the 20-day exponential moving average had functioned as a near-perfect intraday support, with multiple sessions wicking down to it and closing well off the lows. On August 19, that support gave way on a wide-range red bar, and the stock closed underneath the 50-day simple moving average for the first time since early April.

Torrent Pharma daily candles, July 21 to September 19, 2025, with 20-DMA, 50-DMA and 200-DMA overlaid Caption: Watch the August 19 close below the 50-DMA, the two failed retests of that line in late August, and the September 4 capitulation low near ₹3,293 before the late-month stabilisation.

What separated this break from the half-dozen shallower dips earlier in 2025 was the behaviour on the retest. Between August 22 and August 29, the stock attempted twice to reclaim the 50-DMA on an intraday basis. Both attempts failed at the close. By the end of August, the 20-DMA had crossed below the 50-DMA on the daily, the first such crossover since the post-October 2024 correction, and the moving-average stack that had been bullish for the better part of a year had inverted at the short end.

Volume confirmed the character of the move. The August 19 down-bar printed on volumes meaningfully above the trailing twenty-session average, and several of the subsequent down-days through late August and into the first week of September carried above-average prints as well. The up-days, by contrast, came on thinner participation. That is the volume signature of distribution rather than orderly profit-taking, and it sat uncomfortably alongside the comforting narrative that this was just a "defensive name taking a breather."

The September 4 session: intraday anatomy of a capitulation low

The 30-minute frame for the run-up to September 4 is where the operator-versus-retail divergence was most legible. From August 30 onward, the stock had been carving a descending series of intraday lower highs, with each morning's opening bounce being sold into by the second or third half-hour bar of the session. Anyone running a simple opening-range strategy on Torrent through that week was getting chopped, because the opening range kept resolving downward.

Torrent Pharma 30-minute candles, August 30 to September 4, 2025 Caption: The terminal flush on September 4, with the morning gap-down to the ₹3,293 area followed by a sharp recovery wick into the close, the classic intraday signature of forced selling meeting a waiting bid.

September 4 itself opened gap-down, traded straight into the ₹3,293 area inside the first hour, and then put in the kind of long-tailed recovery candle on the 30-minute frame that hindsight is kind to. The session closed well off the lows on visibly elevated volume, the largest single-day turnover Torrent had seen in the entire 44-session window. Whoever was forced out at the open found a buyer who was not in a hurry, and the close-versus-low spread on that day, in percentage terms, was the widest of the correction.

In tape-reading terms, this was a classic shake-out: a price extension to a round level, a volume spike that suggested capitulation rather than initiation, and a recovery into the close that left the daily candle as a hammer below the 50-DMA. It did not, by itself, mark the end of the corrective phase, but in retrospect it marked the point at which the downside risk-reward shifted.

The fundamental backdrop: a beat that aged poorly

The Q1 FY26 print that Torrent had delivered in early August was, on the face of it, supportive. The domestic formulations business had continued to grow at a healthy mid-teens pace, the chronic-therapy mix had ticked up again, and operating margins had come in ahead of street expectations on the back of a softer raw-material cycle and the residual benefit of the prior year's price hikes in the NLEM-exempt portfolio.

Brokerage notes through August had broadly reiterated their constructive stance, with target prices in a band that implied modest upside from the late-July levels rather than meaningful re-rating. That was the problem. When a defensive large-cap is trading at the upper end of its historical multiple band and the consensus target offers single-digit upside, the marginal buyer has to come from somewhere other than the fundamental cohort. Through July, that marginal buyer had been momentum-driven, and once the daily structure broke on August 19, that cohort had no reason to defend the position.

Peer behaviour reinforced the read. The broader pharma index held up better than Torrent through the same window, with select US-generic names actually advancing on the back of a softer dollar and renewed FDA-clearance newsflow. The relative-strength line of Torrent versus Nifty Pharma rolled over in mid-August and did not recover through the September 4 low. This was not sector weakness expressing itself through Torrent; this was Torrent-specific positioning unwind inside a sector that was otherwise stable.

Derivatives: the quiet repricing in the option chain

The September monthly option chain, in the five sessions either side of September 4, told a story that the cash market was only beginning to acknowledge. Open interest on the ₹3,300 and ₹3,400 puts built up steadily through the last week of August into the first week of September, with the put-call ratio at those strikes drifting in a direction that was consistent with hedging rather than directional shorting. Stock futures open interest also rose on the down-days, which alongside the falling spot price was the textbook signature of fresh short positions being initiated rather than long positions being unwound.

FII derivative positioning across the broader pharma basket through August had been a modest net-long, but the stock-specific lean in Torrent futures showed long unwinding through the second half of August and early September. By the September 4 close, the cumulative change-in-OI on Torrent futures over the prior fortnight was the largest two-week build the contract had seen in the calendar year. The September 4 hammer might have marked the intraday capitulation in cash, but in derivatives the positioning shift had been telegraphed for at least two weeks.

Historical analogs: this had happened before

The setup of a defensive large-cap pharma running into a 50-DMA break after an extended advance was not new to Torrent's chart. A similar sequence had played out in October to November 2024, when the stock had given back roughly 7% over six weeks after a comparable extension, only to bottom on a volume capitulation day and grind back to fresh highs through the first quarter of 2025. The 2024 analog had also featured a weekly RSI negative divergence at the highs, a daily moving-average inversion at the short end, and a derivative-led repricing that preceded the cash-market low.

What the analog suggested, and what the subsequent tape through the back half of September 2025 partially confirmed, was that these corrections in Torrent had historically been sharper in time than in price. The 5.4% drawdown from July 21 to September 4 was, by the standards of the stock's prior corrective phases, neither shallow enough to dismiss nor deep enough to indicate a structural break. The weekly trend channel from late 2023, even after the September 4 low, remained intact on a closing basis.

Verdict

Stance: NEUTRAL Horizon: 5d / 1mo / 3mo Rationale: Ex-post, the 5.4% slide was a structurally healthy mean reversion in a stock that had run two standard deviations above its 40-week mean by late July, with the September 4 hammer marking the most likely intraday low of the corrective phase, though reclaim of the 50-DMA was the precondition for any fresh long, and on the September 4 close that precondition had not yet been met.